Kornimate/medical-research-clean huggingface dataset:
comparative effects of therapeutic ultrasound and sinus massage in chronic rhinosinusitis: a randomized controlled study

Conditions: Chronic Rhinosinusitis (CRS)

Summary: this is a randomized controlled trial. previous studies show that both therapeutic ultrasound and sinus massage techniques have significant results in chronic rhinosinustis (crs). however, there is no comparative study carried out between these two to show which technique has more effects in crs. this study will determine their comparative effects on: 1. pain measured on numerical pain rating scale 2. sinonasal symptoms measured on sino-nasal outcome test questionaire 3. quality of life measured on rhinosinusitis disability index (rsdi) 4. nasal inspiratory airflow measured on peak nasal inspiratory flow meter. participants of chronic rhinosinusitis will be selected according to the diagnostic criteria of american academy of otolaryngology-head and neck surgery foundation (aao-hnsf) and will be randomly allocated into three groups. all three group will continue to receive medical intervention. additionally one group will receive therapeutic ultrasound while other group will receive sinus massage. whereas third group will be control group and won't receive any additional treatment. data will be collected at foundation university college of physical therapy and fauji foundation hospital.


Eligibility criteria:
inclusion criteria: * age 20-60 years * both gender * diagnosed patients of chronic rhinosinusitis referred by an ent specialist * according to the aao-hns, patients are diagnosed with crs if they had: * two or more major symptoms for ≥12 weeks. or * one major symptom with two minor symptoms for ≥12 weeks (19) major clinical symptoms * pain or pressure on the face * nasal congestion * mucopurulent rhinorrhea either anteriorly, posteriorly, or both * hyposmia/anosmia minor clinical symptoms * headache * fever * pain in the dental area * halitosis * pain or pressure on the ear * cough exclusion criteria: * nasal polyps * current medical conditions in which ultrasound is contraindicated (20) * facial metal implants * face or head tumor/cyst/malignancy * deteriorated cognitive level * previous surgery on the nose * facial bone fracture * reduced heat perception * ischemic tissues * skin allergies/lesions to the face

Keywords: chronic rhinosinusitis therapeutic ultrasound sinus massage
managing epilepsy well- webease project

Conditions: Epilepsy

Summary: the purpose of this study is to test a computer program for people with epilepsy. the program was developed to help people with epilepsy improve their self-management skills for taking medications, reducing stress, and sleeping well.

webease is an internet self-management program for people with epilepsy. our goal is to offer a program that supports the management of epilepsy by people with epilepsy. the program is based on proven techniques of motivational interviewing and stages of change. before offering webease to the general public, we tested the program among volunteers with epilepsy. we recruited individuals with epilepsy who were willing to use the program. the program was developed by a team of researchers and physicians who treat patients with epilepsy. the program offers information on three major topics: 1) medication taking, 2) stress and 3) sleep management as it relates to epilepsy. it includes quizzes, fact sheets, and links to other authoritative websites on epilepsy. before beginning the study, each participant completed a brief survey about medications, stress, and sleep. then participants worked through the webease program. webease consists of three modules: medication, stress, and sleep. each module lasts 2 weeks, and includes an interactive session geared specifically to each person's needs. during the study, each participant kept a diary of medications, stress, sleep, and seizures, which allowed them to see changes over time. after completing the webease program, participants completed two more brief surveys about six weeks apart. about half of the participants were asked to complete two surveys about 6 weeks apart before beginning the webease program. these individuals completed one survey after the end of the program.

Eligibility criteria:
inclusion criteria: * be 18 years of age or older * understand and speak english * have been diagnosed with epilepsy * have been on an antiepileptic medication (aed) for at least 3 months * have access to the internet * be willing to participate * have not participated in webease in the past exclusion criteria: * under age 18 * unable to understand and speak english * have not been diagnosed with epilepsy * have not been on an aed for at least 3 months * not willing to participate * have participated in webease in the past

Keywords: epilepsy medication stress sleep lifestyle management
a trial to compare the incidence of squamous cell carcinoma (scc) and other skin neoplasia on skin areas treated with ingenol disoxate gel or vehicle gel for actinic keratosis on face and chest or scalp

Conditions: Actinic Keratosis; Squamous Cell Carcinoma

Summary: one of the main reasons for treating actinic keratoses (ak) is the wish to lower the risk of progression of ak to squamous cell carcinoma (scc). this risk is in the order of 1 per 1000 aks per year, which is in itself a small risk, but since patients can have dozens of aks and the disease is chronic the cumulative risk for a patient can be substantial. in this extension protocol of trials lp0084-1193, -1194, -1195 and -1196, leo will study the incidence of sccs and other skin neoplasia in vehicle and ingenol disoxate treated patients over a period of 2 years, so that the total follow-up time for each patient will be 3 years and 2 months.


Eligibility criteria:
inclusion criteria: * signed and dated informed consent has been obtained. * the subject has been treated in one of the trials lp0084-1193, -1194, -1195, or -1196 and has been evaluated at the end of follow-up visit (month 14) of that trial. exclusion criteria: * the subject is in need of treatment with ingenol mebutate or ingenol disoxate in the selected treatment area . * the subject is enrolled in any other interventional clinical trial. for subjects where there is a gap between end of follow-up visit (month 14) in one of the trials lp0084-1193, -1194, -1195, or -1196 and participation in the current trial: * the subject has been treated with ingenol mebutate or ingenol disoxate in the selected treatment area after end of follow-up visit (month 14) in one of the trials lp0084-1193, -1194, -1195, or -1196 and until participation in the current trial. * the subject has been enrolled in any other interventional clinical trial after end of follow-up visit (month 14) in one of the trials lp0084-1193, -1194, -1195, or -1196 and until participation in the current trial.
the effect of breathing exercise applied to intensive care nurses on fatigue and perceived stress

Conditions: Breathing Exercises; Critical Care Nursing

Summary: the aim of this randomized controlled trial was to investigate the effect of breathing exercise on fatigue and stress in intensive care nurses. hypotheses of the study; h11: the level of perceived stress in nurses practicing breathing exercise is lower than the nurses in the control group. h12: the level of fatigue is lower in nurses practicing breathing exercise compared to nurses in the control group. data will be collected in the intervention and control groups with a pre-test data collection form before the intervention. patients in the intervention group will be given breathing exercises, while patients in the control group will not receive any intervention. in the second week, interim follow-up data will be collected with the data collection form. at the end of the study; data will be collected from the intervention and control groups with post-test data collection forms.

in line with the randomization list, nurses will be assigned to the intervention and control groups in line with the inclusion criteria. the nurses will be informed about the study and their written and verbal consent will be obtained to participate in the study. data will be collected from the nurses in the intervention and control groups with a pre-test data collection form. the nurses in the intervention group will be given breathing exercise practice, while the patients in the control group will not be subjected to any intervention. in the research; triple breathing technique (full yogic breathing) and 4-7-8 breathing technique will be used. in the intervention group, the nurses will first be told face-to-face about the breathing practice and have them do it. then, face-to-face practice will be done three days a week, and on the other days, an audio recording of the breathing exercise will be sent by the researcher to the nurses via whatsapp and they will be practiced daily. breathing exercise will continue for 30 days in the intervention group. follow-up data will be collected from the control and intervention group on the 15th day as an interim follow-up (with piper fatigue scale and perceived stress scale). on the 30th day, the research will be finalized by collecting the post-test data. at the end of the study, the nurses in the control group will be shown and practiced breathing exercises.

Eligibility criteria:
inclusion criteria: * working in intensive care for at least 6 months * volunteering to participate in the research * not practicing any complementary therapies during the study, such as breathing exercises, acupuncture, massage therapy, relaxation techniques and yoga, which may be effective on perceived stress and fatigue exclusion criteria: * having a problem that prevents nasal breathing and prevents breathing exercises * being pregnant * experiencing physical and mental health problems that prevent communication

Keywords: stress nurse intensive care
verification study of ciclosporin for atopic dermatitis

Conditions: Severe Atopic Dermatitis

Summary: to assess the efficacy and safety of oral ol27-400mepc 3 mg/kg/day (2-5 mg/kg/day) in 2 divided doses daily for 8 weeks to patients with severe adult atopic dermatitis. this study is not enrolling patients in the united states


Eligibility criteria:
inclusion criteria: * appropriate the definition/diagnosis criteria of atopic dermatitis of the japanese dermatological association * patients with severest atopic dermatitis \[according to the "guidelines for treatment of atopic dermatitis 2002, the severity of atopic dermatitis will be classified as severest when an eruption associated with severe inflammation (a lesion associated with erythema, papule, erosion, infiltration, lichenification, etc.) is noted on at least 30% of body surface on the day of subject enrollment\]. exclusion criteria: * - patients who received oral preparations, injections, inhaled preparations and suppositories of steroids or immunosuppressants other than tacrolimus hydrate ointments within 14 days of subject enrollment * patients who might receive the oral/injection drugs which are known to enhance nephrotoxicity, increase serum potassium levels, hmg-coa reductase inhibitors or theophylline during the treatment period. * patients who received or are receiving an ultraviolet therapy (puva therapy, etc.) * patients with hypertension, active infectional disease, gout etc. other protocol-defined exclusion criteria may apply

Keywords: atopic dermatitis, ciclosporin,
vascular malformations and abnormalities of growth

Conditions: Abnormality

Summary: to take part in this study you/your child have a vascular malformation, a type of blood vessel disorder whose cause is unknown. the investigators will do this by looking at changes in the genes and proteins in the cells of the malformation as well as normal cells. the investigators are doing this research because currently there is no known cause of vascular malformations and no way to know whether or not other health problems will occur in addition to the malformation. through this research we hope to create standard methods for doctors to examine and treat people with vascular anomalies.

if you/your child agree to participate 1. informed consent and permission to use or disclose you/your child's health information for reserve purposes will be obtained by the research team. you will receive a copy of the consent form. 2. you/your child will be examined by a physician from the research team and interviewed about your medical background and condition every year for five years. 3. you/your child will have photographs taken of the affected area at each visit. 4. you/your child will have two, one time biopsies or skin samples taken by a dermatologist. skin areas will be numbed with lidocaine and a 4 or 5 millimeter (or approximately 0.15 to 0.19 inch) sample will be taken in two different locations. the dermatologist taking the skin sample will use every effort to choose an area that can be covered by clothing or kept out of sight to others. the doctor will either use gelfoam or one stitch/suture per biopsy to seal off the area, which helps with healing and preventing bleeding. if a stitch is placed in the biopsy site, another visit about 7-10 days following the procedure will be necessary to remove the stitch. 5. you may still participate in the study if you consent to having only one biopsy taken of your affected (lesion) skin and not one of your unaffected (normal) skin.

Eligibility criteria:
inclusion criteria: * greater than 1 year of age * diagnosis of vascular malformation * each patient's authorized legal guardian must understand the nature of the study and must provide written informed consent. each patient must also give assent to study participation given they have the cognitive capacity to do so. exclusion criteria: * patients less than 1 year of age * vascular malformations likely to result in poor wound healing or located in areas of the body prone to significant scarring * individuals with vascular malformations and previous diagnosis of disseminated intravascular coagulopathy

Keywords: vascular malformation vascular anomalies abnormalities of growth overgrowth subjects with vascular malformations abnormalities of growth.
fruquintinib with pd-1 inhibitors versus tas-102 with bevacizumab in late-line mcrc

Conditions: Metastatic Colorectal Adenocarcinoma

Summary: fruquintinib with pd-1 inhibitors (fp) and tas-102 with bevacizumab (tb) are two common therapies for patients with previous-treated metastatic colorectal cancer (mcrc). however, it's still not clear that which therapy can bring better prognosis. our study sought to investigate the efficacy and safety of fruquintinib with pd-1 inhibitors versus tas-102 with bevacizumab in late-line mcrc between july 2019 to october 2022july 2019 and june 2021 at the hunan cancer hospital.

this is a retrospective cohort study conducted in hunan cancer hospital. patients (pts) with mcrc who had received at least the 2nd line treatment were eligible. propensity score (ps) would be calculated to balance the baseline characteristics of two arms. overall survival (os) was set as the primary endpoint. from july 2019 to october 2022, 106 eligible pts in total were enrolled. according to the treatment received, 72 and 34 pts were respectively allocated into fp cohort and tb cohort.

Eligibility criteria:
inclusion criteria: 1. has histologically confirmed unresectable adenocarcinoma of the colon or rectum (all other histological types are excluded). 2. have progressed from at least 2 lines of standard treatment,including fluoropyrimidines, irinotecan, oxaliplatin, with or without targeted drugs, like bevacizumab and cetuximab (only for ras wild-type). regorafenib was permitted but not required for inclusion. 3. has measurable or non-measurable disease as defined by recist version 1.1 4. is able to swallow oral tablets. 5. estimated life expectancy ≥12 weeks. 6. eastern cooperative oncology group performance status (ecog ps) less than 2 7. has adequate organ function. exclusion criteria: 1. pregnancy, lactating female or possibility of becoming pregnant during the study. 2. has not recovered from clinically relevant non-hematologic ctcae grade ≥ 3 toxicity of previous anticancer therapy (excluding alopecia, and skin pigmentation). 3. has symptomatic central nervous system metastases that are neurologically unstable or requiring increasing doses of steroids to control cns disease. 4. has severe or uncontrolled active acute or chronic infection. 5. known carriers of hiv antibodies. 6. confirmed uncontrolled arterial hypertension or uncontrolled or symptomatic arrhythmia.

Keywords: colorectal cancer; fruquintinib;pd-1;tas-102; bevacizumab
treatment of attention-deficit/hyperactivity disorder (adhd) with atomoxetine in young adults and its effects on functional outcomes

Conditions: Attention Deficit Hyperactivity Disorder

Summary: this study will evaluate atomoxetine's efficacy in treating attention-deficit/hyperactivity disorder (adhd) symptoms and atomoxetine's effect on functional outcomes in young adults. a gatekeeper strategy will be employed for sequentially testing the secondary objectives. this study also has an observational community sample arm in which patients will complete all the efficacy measurements via web-based self reporting.


Eligibility criteria:
inclusion criteria: * positive attention-deficit/hyperactivity disorder (adhd) diagnosis with at least moderate severity * male or female 18 to 30 years of age * must be able to swallow capsules * must be able to communicate effectively in english * must not have cognitive impairment * be reliable to keep appointments for clinic visits and all related tests exclusion criteria: * patients diagnosed with obsessive-compulsive disorder, bipolar affective disorder, or psychosis * females who are pregnant or breastfeeding * patients with dementia or traumatic brain injury * patients with a history of severe allergy to atomoxetine * have untreated hypertension or thyroid problem * have serious medical illness including any heart, liver, kidney, respiratory, blood, endocrine, or neuromuscular diseases
candidate clinical correlate of prognostic outcome for tb study

Conditions: Tuberculosis

Summary: as part of the ongoing efforts within the rapid research in diagnostics development for tb network (r2d2 tb network) study, the candidate clinical correlate as prognostic outcome for tb (c3po) study serves as a supplement aimed at evaluating predictors and novel biomarkers of recurrent tb among tb survivors. current tools for predicting tb recurrence risk are suboptimal, limiting the ability to assess new tb treatment regimens effectively. identifying accurate sputum- or blood-based biomarkers for recurrence risk could significantly improve the efficiency and informativeness of phase 2 and 3 clinical trials.

the candidate clinical correlate as prognostic outcome for tb study (c3po) supplements the ongoing rapid research in diagnostics development for tb network (r2d2 tb network) study by identifying and accelerating novel tb diagnostics at various stages of development and across different use cases. there is an urgent need for treatments that can cure all forms of tb more quickly. however, the development of new, shorter, and more effective antibiotic regimens is hindered by the limitations of current methods used to assess treatment effectiveness in tb drug trials. the standard pharmacodynamic (pd) marker-sputum culture-does not predict clinical outcomes well, fails to detect residual mycobacterium tuberculosis that causes relapse, and takes 6-8 weeks to provide results. new pd markers that more accurately predict clinical outcomes would help de-risk clinical trials and ensure that only the most effective new regimens move forward. c3po aims to evaluate non-culture pd markers in predicting recurrent tb among patients who have completed the global standard hrze regimen for drug-susceptible pulmonary tb under routine programmatic settings.

Eligibility criteria:
inclusion criteria: 1. . individuals age ≥ 12 years; 2. . have completed treatment for drug-susceptible tuberculosis with the standard 6-month regimen of isoniazid, rifampin, pyrazinamide, and ethambutol (hrze). exclusion criteria: 1. completed treatment for drug-susceptible tuberculosis \>14 days prior to screening/enrollment; 2. routinely taking any medication with anti-mycobacterial activity (including fluoroquinolones) for any reason not related to tuberculosis treatment within the last 14 days; 3. unwilling to provide informed consent or return for study follow-up visits.

Keywords: tuberculosis global health diagnostics
a long-term safety study of infliximab (remicade)

Conditions: Arthritis, Rheumatoid; Crohn Disease; Psoriasis

Summary: this is a study evaluating the long-term safety of infliximab (remicade)

the purpose of this study is to collect long-term safety information on infliximab (remicade) from patients who participate in research studies using those drugs. all patients in these studies are being asked to participate in this long-term safety follow-up study which will provide important information about the study drug. the long-term effect of the study drug on survival, serious infections, new malignancies and new autoimmune diseases will be measured from data collected over a 5-year period. additional information about possible delayed allergic reactions (possible fever, rash, fatigue, joint pain) will also be collected if you received infliximab (remicade) after the end of the primary study. study participation in this research study is 5 years after the end of the primary study. questionnaires will be completed about patient's health and the occurrence of these safety events at intervals of 6 months, 1 year, 2 years, 3 years, 4 years and 5 years after patients complete participation in the primary study.

Eligibility criteria:
inclusion criteria: * all patients enrolled in ongoing and future centocor sponsored infliximab clinical studies that require long-term safety follow-up (ie, primary studies). patients must have received at least 1 dose of study agent to be eligible for participation in the study exclusion criteria: - did not previously participate in centocor sponsored infliximab clinical studies.

Keywords: rheumatoid arthritis crohn's disease psoriasis